You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BrCa

Showing 1 - 25 of 916
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES

Not yet recruiting
  • BRCA Mutation
  • +2 more
  • Germinal BRCA
  • (no location specified)
Mar 3, 2023

Germline Variant Carriers With BRCA1 or BRCA2

Recruiting
  • BRCA1 and/or BRCA2 Variant Carriers
  • +3 more
    • Okayama, Japan
      Okayama University
    Dec 25, 2022

    Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

    Not yet recruiting
    • Breast Cancer
    • +7 more
    • (no location specified)
    Sep 26, 2023

    Breast Cancer, Genetic Disease, BRCA2 Mutation Trial (blood sample for BRCA2 mutation detection)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • blood sample for BRCA2 mutation detection
    • (no location specified)
    Jun 1, 2023

    BRCA and NACT in TNBC Patients

    Completed
    • Triple-Negative Breast Cancer
    • BRCA1/2 genetic testing
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

    Enrolling by invitation
    • Breast Cancer
    • +7 more
    • Dnipro, Ukraine
    • +1 more
    Jun 17, 2023

    Ultra-rapid BRCA1/2 Status Screening Test in Theranostic

    Not yet recruiting
    • Breast Cancer
    • Questionnaires
    • Communication of the results of the BRCA1/2 ultra rapid test
    • (no location specified)
    Oct 26, 2023

    Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)

    Enrolling by invitation
    • Germline BRCA-mutated HER2-negative Breast Cancer
    • Beijing, Beijing, China
      Breast Cancer, Peking University People's Hospital
    Nov 14, 2022

    Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)

    Not yet recruiting
    • Triple Negative Breast Neoplasms
    • +7 more
    • (no location specified)
    Aug 1, 2022

    Breast Cancer, Genetic Predisposition Trial in Rome, Varese (Genetic predisposition to breast cancer)

    Recruiting
    • Breast Cancer
    • Genetic Predisposition
    • Genetic predisposition to breast cancer
    • Rome, Italy
    • +1 more
    May 4, 2023

    Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)

    Active, not recruiting
    • Breast Cancer
    • +3 more
    • Boston, Massachusetts
    • +2 more
    Dec 21, 2022

    BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer Trial in Providence (Talazoparib Oral Capsule)

    Active, not recruiting
    • BRCA1 Mutation
    • +4 more
    • Talazoparib Oral Capsule
    • Providence, Rhode Island
    • +1 more
    Nov 30, 2022

    Quality of Sexual Function in BRCA Mutated Women

    Recruiting
    • BRCA Mutation
    • +3 more
    • SFQ28 Questionnaire
    • Brescia, BS, Italy
      Federico Ferrari
    Jul 10, 2022

    BRCA1/2 Flu Vaccine

    Active, not recruiting
    • BRCA1 Mutation
    • BRCA2 Mutation
    • Seasonal influenza vaccine
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Aug 16, 2022

    TNBC - Triple-Negative Breast Cancer Trial in Nanjing (Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide)

    Recruiting
    • TNBC - Triple-Negative Breast Cancer
    • Nanjing, Jiangsu, China
      JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
    Apr 27, 2023

    Breast Cancer Trial in Los Angeles (Pembrolizumab, Olaparib)

    Active, not recruiting
    • Breast Cancer
    • Los Angeles, California
      Cedars-Sinai Medical Center
    Feb 1, 2023

    Endocrine Disruptors and Life STILe in Breast Cancer Development

    Recruiting
    • Breast Cancer
    • +5 more
      • Roma, Italy
        Alessandra Fabi
      Feb 25, 2023

      Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

      Not yet recruiting
      • Ovarian Cancer
      • +4 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Cetntre
      Sep 25, 2023

      Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer Trial in United States (Niraparib, Dostarlimab)

      Recruiting
      • Stage I Breast Cancer
      • +7 more
      • Baltimore, Maryland
      • +6 more
      Nov 11, 2022

      Breast Cancer With or Without BRCA Mutation

      Recruiting
      • Breast Cancer
      • Androgen receptor status and BRCA mutation
      • Varanasi, UP, India
        Banaras Hindu University
      Jun 2, 2022

      Ovarian Cancer Trial (Huaier granule)

      Not yet recruiting
      • Ovarian Cancer
      • Huaier granule
      • (no location specified)
      Feb 28, 2023

      Breast Tumor Female Trial in United Kingdom (Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform,

      Active, not recruiting
      • Breast Neoplasm Female
      • Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform
      • Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform
      • Manchester, England, United Kingdom
      • +4 more
      Aug 12, 2022

      Breast Cancer After Ovarian Cancer During and/or After Therapy:

      Recruiting
      • BRCA-Associated Breast Carcinoma
      • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
      • Rome, RM, Italy
        Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      Mar 9, 2023

      BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Columbus (Informational Intervention, Survey Administration)

      Recruiting
      • BRCA1 Gene Mutation
      • BRCA2 Gene Mutation
      • Informational Intervention
      • Survey Administration
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Mar 2, 2022

      Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

      Not yet recruiting
      • Metastatic Solid Tumor
      • +4 more
      • San Francisco, California
        University of California, San Francisco
      Jan 12, 2023